Last $0.19 USD
Change Today 0.00 / 0.00%
Volume 0.0
RVALL On Other Exchanges
Symbol
Exchange
Frankfurt
OTC US
As of 4:30 PM 05/7/14 All times are local (Market data is delayed by at least 15 minutes).

reva medical inc - cdi (RVALL) Snapshot

Open
--
Previous Close
$0.19
Day High
--
Day Low
--
52 Week High
12/13/13 - $0.52
52 Week Low
03/31/14 - $0.19
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
334.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REVA MEDICAL INC - CDI (RVALL)

Related News

No related news articles were found.

reva medical inc - cdi (RVALL) Related Businessweek News

No Related Businessweek News Found

reva medical inc - cdi (RVALL) Details

REVA Medical, Inc., a development stage medical device company, focuses on the development and commercialization of proprietary bioresorbable stent products. The company is developing and testing a bioresorbable stent to treat vascular disease in humans. Its products include ReZolve scaffold, a drug-eluting fully bioresorbable polymer stent to degrade and clear from the body. The company is also developing ReZolve2 scaffold, a drug-eluting fully bioresorbable polymer stent that is implanted using a balloon catheter to provide X-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.

Founded in 1998

reva medical inc - cdi (RVALL) Top Compensated Officers

Co-founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $359.7K
President and Chief Operating Officer
Total Annual Compensation: $340.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.2K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $260.9K
Senior Vice President of Product Development
Total Annual Compensation: $254.0K
Compensation as of Fiscal Year 2013.

reva medical inc - cdi (RVALL) Key Developments

REVA Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

REVA Medical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, loss from operations was $4.8 million against $6.7 million last year. Net loss attributable to common stockholders was $4.8 million or $0.14 per basic and diluted share against $6.6 million or $0.20 per basic and diluted share last year. For the six months, loss from operations was $12.1 million against $13.0 million last year. Net loss attributable to common stockholders was $12.1 million or $0.36 per basic and diluted share against $13 million or $0.39 per basic and diluted share last year. Net cash used for operating activities was $10.8 million against $10.6 million last year. The decrease in net loss from the corresponding period in the prior year primarily reflects a decrease in research and development expenses following the company's change in March 2014 from its ReZolve®2 program work to the development and testing of its FantomTM scaffold. Upon the change, an approximate 45% reduction in headcount was made and a reduction of other costs was implemented.

REVA Medical, Inc., Q2 2014 Earnings Call, Aug 13, 2014

REVA Medical, Inc., Q2 2014 Earnings Call, Aug 13, 2014

REVA Medical, Inc. Reports Consolidated Cash Flow Results for the Second Quarter and Six Months Ended June 30, 2014

REVA Medical, Inc. reported consolidated cash flow results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported negative net operating cash flows of $4,181,000 and payment for acquisition of physical non-current assets was $121,000. For the six months, the company reported negative net operating cash flows of $338,000 and payment for acquisition of physical non-current assets was $338,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RVALL:US $0.19 USD 0.00

RVALL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RVALL.
View Industry Companies
 

Industry Analysis

RVALL

Industry Average

Valuation RVALL Industry Range
No financial data is available for RVALL.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVA MEDICAL INC - CDI, please visit www.revamedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.